A significant milestone just appeared on ClinicalTrials.gov: the Phase 3 study titled A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (NCT05929079) has moved from actively enrolling to completed, with a primary completion date of June 16, 2026. For the thousands of people tracking retatrutide — commonly referred to as reta in patient communities — this is one of the most consequential updates yet. Here is a plain-language breakdown of what this trial studied, what the data already suggests, and what trial completion realistically means for the path to FDA approval.
Retatrutide is a once-weekly subcutaneous injection developed by Eli Lilly and Company. It is a triple hormone receptor agonist, activating the GLP-1, GIP, and glucagon receptors simultaneously — a mechanism sometimes called triple G in patient communities to distinguish it from dual agonists like tirzepatide. By engaging all three receptor pathways, retatrutide addresses appetite signaling, glucose metabolism, and energy expenditure through complementary biological mechanisms.
The completed Phase 3 trial, identified as NCT05929079, specifically studied retatrutide in participants who have both type 2 diabetes mellitus and obesity or overweight. This is an important distinction from earlier Phase 2 data, which excluded participants with type 2 diabetes entirely. Studying this population allows Eli Lilly to evaluate retatrutide's efficacy and safety profile in a group where weight loss, glycemic control, and cardiometabolic risk often intersect in complex ways. Completion of this trial marks a critical data collection endpoint on the regulatory timeline.
Full peer-reviewed results from NCT05929079 have not yet been published as of April 2026. However, the broader TRIUMPH Phase 3 program has already produced striking data. The TRIUMPH-4 trial — a 68-week Phase 3 study in adults with obesity — reported a mean weight loss of 28.7% at the 12mg dose, which Eli Lilly described in a December 2025 press release as the highest mean weight loss ever recorded in a Phase 3 obesity clinical trial.
To put that figure in context, the table below compares TRIUMPH-4 results against the landmark Phase 3 trials for the two currently approved injectable weight loss medications:
| Drug | Trial | Duration | Mean Weight Loss (Highest Dose) | Population |
|---|---|---|---|---|
| Semaglutide 2.4mg | STEP-1 | 68 weeks | ~14.9% | Obesity, no T2D |
| Tirzepatide 15mg | SURMOUNT-1 | 72 weeks | ~20.9% | Obesity, no T2D |
| Retatrutide 12mg | TRIUMPH-4 | 68 weeks | ~28.7% | Obesity, no T2D |
Earlier Phase 2 data from the NEJM 2023 publication (Jastreboff et al.; NCT04881760) had already signaled retatrutide's exceptional potential. At 48 weeks, participants in the 12mg arm achieved a mean weight loss of approximately 24.2%, and 48% of participants lost 25% or more of their body weight. In the 8mg arm, 100% of participants achieved at least 5% weight loss — an unprecedented threshold in obesity pharmacology. Many participants who have tried earlier medications and still struggled with persistent hunger and food noise described in the Phase 2 trial's quality-of-life measures (SF-36v2) significant improvements across all active dose groups at week 48.
Regarding safety, the most common adverse events in Phase 2 were gastrointestinal — nausea, diarrhea, and vomiting — consistent with the GLP-1 class and most pronounced during dose titration. TRIUMPH-4 introduced a careful five-step titration schedule: 2mg (weeks 1–4), 4mg (weeks 5–8), 6mg (weeks 9–12), 9mg (weeks 13–16), and 12mg as the maintenance dose from week 17 onward. One notable adverse event at higher doses is dysesthesia — an abnormal skin sensation — reported in 20.9% of the 12mg group in TRIUMPH-4, compared with 0.7% of the placebo group. Discontinuation rates were 18.2% at 12mg versus 4.0% for placebo. These are important considerations that clinicians and patients will need to weigh carefully when retatrutide becomes available.
Trial completion is a necessary — but not sufficient — step toward FDA approval. When a Phase 3 trial moves to completed status, it signals that the primary data collection period has closed and Eli Lilly's teams can begin the formal process of analyzing results, preparing the clinical study report, and compiling a New Drug Application (NDA) package for submission to the FDA.
As of April 2026, Eli Lilly has not yet filed an NDA for retatrutide, and no FDA approval timeline has been publicly confirmed. The full peer-reviewed Phase 3 publication is also still pending. Each of these steps takes time — NDA preparation, FDA filing, Priority Review designation assessment, and the standard review clock of six to twelve months all sit between a completed trial and a drug on the pharmacy shelf.
What trial completion does mean is that the data now exists. The clinical story for retatrutide — across obesity without diabetes and now, potentially, obesity with type 2 diabetes — is becoming more complete. That is meaningful progress on a regulatory pathway that has moved faster than many anticipated.
Realistic timelines remain speculative. If Eli Lilly files an NDA in late 2026, a standard FDA review could conclude sometime in 2027, though Priority Review designation — if granted — could shorten that window. Regulatory processes do not follow fixed calendars, and additional Phase 3 results from NCT05929079 and other TRIUMPH program trials will need to be incorporated into the submission package.
For patients who have spent years navigating the limitations of currently available options, or who have found that existing GLP-1 medications did not produce sufficient results, the completion of this trial is a concrete sign that retatrutide is advancing. The combination of 28.7% mean weight loss in TRIUMPH-4, robust Phase 2 cardiometabolic improvements — including triglyceride reductions of up to 39.3% and LDL reductions near 17% at 24 weeks — and now a completed diabesity-focused Phase 3 trial represents a genuinely differentiated clinical profile.
Staying informed as this data matures is one of the most practical things a prospective patient can do right now. glp3md.com maintains an active waitlist designed to keep interested patients up to date on retatrutide's regulatory progress, trial publications, and prescribing availability as it develops. Joining the waitlist makes no promises about medication access or treatment — retatrutide is not FDA-approved, and waitlist registration is for informational purposes only. But when approvals, prescribing guidelines, and availability news break, waitlist members will be among the first to know. Visit glp3md.com to add your name and stay ahead of the most significant development in obesity medicine in a generation.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.